Some patients diagnosed with NT2 may later develop cataplexy, or with CSF‐HCRT1 deficiency, thus requiring re‐labelling as NT1 (Baumann‐Vogel et al. 2021; Andlauer et al. 2012). Here, HCRT is linked to Cataplexy.